

FOI 2752

19th November 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question:

Please could you give us current information in relation to how prostate cancer patients are managed when they are eligible for active surveillance/monitoring. Including:

- **Inclusion criteria**
- **Diagnosis and treatment decision support**
- **Follow-up pathways and protocols**
- **Follow-up testing frequencies**
- **Triggers for stopping active surveillance**

Response:

Patients who are suitable for active surveillance, as per NICE prostate cancer guidelines are identified at Multi-disciplinary meeting (MDM) and offered it as a treatment option or recommendation as appropriate at consultation with the clinical team.

Patient support is provided by a Clinical Nurse Specialist team at the time of the consultations with all patients provided with a key worker name and contact details, along with written information regarding the treatment options (using Prostate cancer UK patient information sheets / booklets).

Eligible patients are followed up by the Clinical Nurse Specialist team, those who don't meet Clinical Nurse Specialist Follow Up clinic criteria are followed up by the medical team, as per NICE recommendations.

All patients who have surveillance biopsies are discussed at Multi-disciplinary meeting regarding suitability for ongoing active surveillance, as are those patients who are on active surveillance and are felt to have progressed to needing treatment based on prostate specific antigen dynamics / MRI changes who haven't had a surveillance biopsy.

Email: Foi.Team@Southerntrust.hscni.net